Design Therapeutics, Inc. Common Stock
$12.24
-$0.57 (-4.45%)
$12.24Day Range$12.88
Key Statistics
Market Cap
$766.00M
Shares Outstanding
62.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 26, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$12.81
Day High
$12.88
Day Low
$12.24
Volume
2.55M
VWAP
$12.30
Prev Close
$12.81
Transactions
--
Acc. Volume
--
About Design Therapeutics, Inc. Common Stock
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
PHARMACEUTICAL PREPARATIONSSIC 283455 employees6005 HIDDEN VALLEY ROAD, CARLSBAD, CA, 92011858-293-4900IPO Mar 26, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001807120
- Composite FIGI
- BBG00SNC49V8
- Share Class FIGI
- BBG00SNC49W7
- Ticker Root
- DSGN
- SIC Code
- 2834
About Design Therapeutics, Inc. Common Stock (DSGN) Stock
Design Therapeutics, Inc. Common Stock (DSGN) closed the 2026-09-18 session at $12.24, down 4.45% versus the previous close (-0.57). The stock opened at $12.81 and traded between $12.24 and $12.88 during that session. Session trading volume was 2.6M shares. The volume-weighted average price (VWAP) is $12.30.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Design Therapeutics, Inc. Common Stock has a market capitalization of $766.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. DSGN is listed on the XNAS exchange. The company employs approximately 55 people. Design Therapeutics, Inc. Common Stock is headquartered in CARLSBAD, CA. The recorded listing date is 2021-03-26.
On this page you can find market DSGN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.